Oakrum Pharma, in collaboration with Aucta Pharmaceuticals, announced the U.S. approval of a generic version of JADENU® Sprinkle (Deferasirox Granules) in 90mg, 180mg, and 360mg strengths.
Deferasirox granules had annual sales in the U.S. exceeding $31 million in the aggregate for the 12-month period ending January 2021 according to available data from IQVIATM.
"The investments that we have made in our product development pipeline since starting this business are expected to provide significant contributions to the growth of Oakrum Pharma over the next couple of years. The launch of Deferasirox Granules is the first of several products that we expect to commercialize over the next 12-18 months. A few of these near-term launches are products developed by Aucta Pharmaceuticals," Marco Polizzi, CEO of Oakrum Pharma, said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
"We are excited to bring another Aucta Pharmaceuticals developed product to the U.S. market through this partnership with Oakrum Pharma. Aucta Pharmaceuticals continues to expand its product portfolio in niche generics and branded specialty products and is anticipating additional approvals and launches in the next 12 months," Shoufeng Li, CEO of Aucta Pharmaceuticals said.